| Item Type | Name |
|
Concept
|
Angiotensin-Converting Enzyme Inhibitors
|
|
Concept
|
Enzyme Inhibitors
|
|
Academic Article
|
Angiotensin-converting enzyme inhibitors and progression of diabetic nephropathy.
|
|
Academic Article
|
Long-term effects of antihypertensive regimens on renal hemodynamics and proteinuria.
|
|
Academic Article
|
Effects of an ACE inhibitor combined with a calcium channel blocker on progression of diabetic nephropathy.
|
|
Academic Article
|
Angiotensin converting enzyme inhibitors and calcium antagonists alone or combined: does the progression of diabetic renal disease differ?
|
|
Academic Article
|
Current issues in treating the hypertensive patient with diabetes: focus on diabetic nephropathy.
|
|
Academic Article
|
Socioeconomic impact of diabetic nephropathy: can we improve the outcome?
|
|
Academic Article
|
Renal mortality associated with non-insulin-dependent diabetes mellitus.
|
|
Academic Article
|
Benefits of combination angiotensin-converting enzyme inhibitor and calcium antagonist therapy for diabetic patients.
|
|
Academic Article
|
Lack of evidence of blood pressure-independent protection by renin-angiotensin system blockade after renal ablation.
|
|
Academic Article
|
Antihypertensive therapy and the risk of type 2 diabetes mellitus.
|
|
Academic Article
|
ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group.
|
|
Academic Article
|
Combined effects of an angiotensin converting enzyme inhibitor and a calcium antagonist on renal injury.
|
|
Academic Article
|
Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy.
|
|
Academic Article
|
Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial.
|
|
Academic Article
|
When to discontinue ACE inhibitors for nephropathy.
|
|
Academic Article
|
Diabetic hypertensive patients: improving their prognosis.
|
|
Academic Article
|
A practical approach to achieving recommended blood pressure goals in diabetic patients.
|
|
Academic Article
|
Type 2 diabetes: RENAAL and IDNT--the emergence of new treatment options.
|
|
Academic Article
|
Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group.
|
|
Academic Article
|
Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?
|
|
Academic Article
|
A perspective on converting enzyme inhibitors and calcium channel antagonists in diabetic renal disease.
|
|
Academic Article
|
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.
|
|
Academic Article
|
Angiotensin-converting enzyme inhibition to enhance vascular health--clinical and research models.
|
|
Academic Article
|
Optimal treatment of hypertension in African Americans. Reaching and maintaining target blood pressure goals.
|
|
Academic Article
|
Impact of an ACE inhibitor and calcium antagonist on microalbuminuria and lipid subfractions in type 2 diabetes: a randomised, multi-centre pilot study.
|
|
Academic Article
|
The evolution of treatment guidelines for diabetic nephropathy. Strategies integrate JNC VI, more recent protocols.
|
|
Academic Article
|
Heart failure as a cause for hospitalization in chronic dialysis patients.
|
|
Academic Article
|
Defining the antihypertensive properties of the angiotensin receptor blocker telmisartan by a practice-based clinical trial.
|
|
Academic Article
|
Design and statistical aspects of the African American Study of Kidney Disease and Hypertension (AASK).
|
|
Academic Article
|
Evaluation and treatment of patients with systemic hypertension.
|
|
Academic Article
|
Comparison of telmisartan vs. valsartan in the treatment of mild to moderate hypertension using ambulatory blood pressure monitoring.
|
|
Academic Article
|
Quality of life measured in a practice-based hypertension trial of an angiotensin receptor blocker.
|
|
Academic Article
|
How high should an ACE inhibitor or angiotensin receptor blocker be dosed in patients with diabetic nephropathy?
|
|
Academic Article
|
How to adjust ACE inhibitors and ARBs in diabetes?
|
|
Academic Article
|
Clinical implications of blockade of the renin-angiotensin system in management of hypertension.
|
|
Academic Article
|
Treatment of the diabetic patient: focus on cardiovascular and renal risk reduction.
|
|
Academic Article
|
The role of calcium antagonists in chronic kidney disease.
|
|
Academic Article
|
Blood pressure control and nephroprotection in diabetes.
|
|
Academic Article
|
The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension.
|
|
Academic Article
|
Implications of albuminuria on kidney disease progression.
|
|
Academic Article
|
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.
|
|
Academic Article
|
ACE inhibitor for a diabetic patient with normal blood pressure?
|
|
Academic Article
|
Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial.
|
|
Academic Article
|
Effect of fixed-dose ACE-inhibitor/calcium channel blocker combination therapy vs. ACE-inhibitor monotherapy on arterial compliance in hypertensive patients with type 2 diabetes.
|
|
Academic Article
|
Is ethnicity a factor in choice of antihypertensive drug?
|
|
Academic Article
|
Rationale and design of a study to evaluate management of proteinuria in patients at high risk for vascular events: the IMPROVE trial.
|
|
Academic Article
|
Angiotensin-converting enzyme gene polymorphism predicts the time-course of blood pressure response to angiotensin converting enzyme inhibition in the AASK trial.
|
|
Academic Article
|
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic renal disease: safety issues.
|
|
Academic Article
|
Clinical importance of microalbuminuria in diabetes and hypertension.
|
|
Academic Article
|
Antihypertensive therapy in the presence of proteinuria.
|
|
Academic Article
|
Combined therapy with a calcium channel blocker and an angiotensin II type 1 receptor blocker.
|
|
Academic Article
|
Blood pressure control in the patient with difficult-to-control hypertension: which agent for which patient?
|
|
Academic Article
|
Slowing nephropathy progression: focus on proteinuria reduction.
|
|
Academic Article
|
Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control.
|
|
Academic Article
|
Who should be treated with combination therapy as initial treatment for hypertension?
|
|
Academic Article
|
Effects of diltiazem or lisinopril on massive proteinuria associated with diabetes mellitus.
|
|
Academic Article
|
Combination therapy with Renin-Angiotensin-aldosterone receptor blockers for hypertension: how far have we come?
|
|
Academic Article
|
ACE inhibitors and ARBs: are they better than other agents to slow nephropathy progression?
|
|
Academic Article
|
The effects of calcium antagonists on renal hemodynamics, urinary protein excretion, and glomerular morphology in diabetic states.
|
|
Academic Article
|
Lowering blood pressure with beta-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 diabetes: results from the GEMINI Trial.
|
|
Academic Article
|
The JNC 7 approach compared to conventional treatment in diabetic patients with hypertension: a double-blind trial of initial monotherapy vs. combination therapy.
|
|
Academic Article
|
Newer combination therapies in the management of hypertension: an update.
|
|
Academic Article
|
Comparison of dual RAAS blockade and higher-dose RAAS inhibition on nephropathy progression.
|
|
Academic Article
|
Changes in kidney function following heart failure treatment: focus on renin-angiotensin system blockade.
|
|
Academic Article
|
Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.
|
|
Academic Article
|
Intervention at lower blood pressure levels to achieve target goals in type 2 diabetes: PRADID (PResión Arterial en DIabéticos tipo Dos) study.
|
|
Academic Article
|
Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study.
|
|
Academic Article
|
Does evidence support renin-angiotensin system blockade for slowing nephropathy progression in elderly persons?
|
|
Academic Article
|
Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension.
|
|
Academic Article
|
Should proteinuria reduction be the criterion for antihypertensive drug selection for patients with kidney disease?
|
|
Academic Article
|
Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans.
|
|
Academic Article
|
Resistant hypertension: an overview of evaluation and treatment.
|
|
Academic Article
|
The current state of RAAS blockade in the treatment of hypertension and proteinuria.
|
|
Academic Article
|
Inhibiting the renin-angiotensin system in patients with type 1 diabetes: is it worth it?
|
|
Academic Article
|
The effect of ruboxistaurin on nephropathy in type 2 diabetes.
|
|
Academic Article
|
Monitoring and managing urinary albumin excretion: practical advice for primary care clinicians.
|
|
Academic Article
|
Predictors of hyperkalemia risk following hypertension control with aldosterone blockade.
|
|
Academic Article
|
Are there effects of renin-angiotensin system antagonists beyond blood pressure control?
|
|
Academic Article
|
Effect of ruboxistaurin on urinary transforming growth factor-beta in patients with diabetic nephropathy and type 2 diabetes.
|
|
Academic Article
|
Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial.
|
|
Academic Article
|
The continuum of blood pressure risk: when is the best time to intervene?
|
|
Academic Article
|
24-hour ambulatory blood pressure in the ACCOMPLISH trial.
|
|
Academic Article
|
Cardiovascular events during differing hypertension therapies in patients with diabetes.
|
|
Academic Article
|
The evolution of antihypertensive therapy: an overview of four decades of experience.
|
|
Academic Article
|
Dual therapy in hypertensive patients with coronary artery disease: the role of calcium channel blockers and beta-blockers.
|
|
Academic Article
|
Influence of microalbuminuria in achieving blood pressure goals.
|
|
Academic Article
|
The diabetes subgroup baseline characteristics of the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial.
|
|
Academic Article
|
Antihypertensive therapy and progression of diabetic renal disease.
|
|
Academic Article
|
Renal effects of antihypertensive medications: an overview.
|
|
Academic Article
|
Are renin-angiotensin-aldosterone system blockers distinguishable based on cardiovascular and renal outcomes in nephropathy?
|
|
Academic Article
|
Management of hypertension in the elderly population.
|
|
Academic Article
|
Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection.
|
|
Academic Article
|
Renal adaptation to the failing heart. Avoiding a 'therapeutic misadventure'.
|
|
Academic Article
|
Trials that matter: the effect of a fixed-dose combination of an Angiotensin-converting enzyme inhibitor and a diuretic on the complications of type 2 diabetes.
|
|
Academic Article
|
Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study.
|
|
Academic Article
|
Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy.
|
|
Academic Article
|
Pediatrics: blood pressure target for renoprotection in children.
|
|
Academic Article
|
Combination therapy in hypertension.
|
|
Academic Article
|
Fixed-dose combination and chronic kidney disease progression: which is the best?
|
|
Academic Article
|
Effects of ACE inhibitors and calcium antagonists alone or combined on progression of diabetic nephropathy.
|
|
Academic Article
|
Intensive blood-pressure control in hypertensive chronic kidney disease.
|
|
Academic Article
|
Renal outcomes in hypertensive Black patients at high cardiovascular risk.
|
|
Academic Article
|
Treatment of renal failure and blood pressure.
|
|
Academic Article
|
ACE inhibitor-mediated attenuation of mesangial cell growth. A role for endothelin.
|
|
Academic Article
|
Evolution of drugs that preserve renal function.
|
|
Academic Article
|
Angiotensin converting enzyme inhibitors or angiotensin receptor blockers in nephropathy from type 2 diabetes.
|
|
Academic Article
|
ACE inhibitors and protection against kidney disease progression in patients with type 2 diabetes: what's the evidence.
|
|
Academic Article
|
A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.
|
|
Academic Article
|
Effects of COX inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and hispanics.
|
|
Academic Article
|
Amlodipine/benazepril combination therapy for hypertensive patients nonresponsive to benazepril monotherapy.
|
|
Academic Article
|
Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study.
|
|
Academic Article
|
Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.
|
|
Academic Article
|
The kidney and cardiovascular risk--implications for management: a consensus statement from the European Society of Hypertension.
|
|
Academic Article
|
Renin-angiotensin blockade and kidney disease.
|
|
Academic Article
|
Dual RAAS blockade is desirable in kidney disease: con.
|
|
Academic Article
|
Renin-angiotensin inhibition in systolic heart failure and chronic kidney disease.
|
|
Academic Article
|
Effects of nebivolol on aortic compliance in patients with diabetes and maximal renin angiotensin system blockade: the EFFORT study.
|
|
Academic Article
|
Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril.
|
|
Academic Article
|
The past, present and future of renin-angiotensin aldosterone system inhibition.
|
|
Academic Article
|
Prediction and management of hyperkalemia across the spectrum of chronic kidney disease.
|
|
Academic Article
|
The contribution of the ACCOMPLISH trial to the treatment of stage 2 hypertension.
|
|
Academic Article
|
Blood pressure, hypertension, RAAS blockade, and drug therapy in diabetic kidney disease.
|
|
Academic Article
|
Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy.
|
|
Academic Article
|
Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.
|
|
Academic Article
|
Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial.
|
|
Academic Article
|
Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.
|
|
Academic Article
|
Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors.
|
|
Academic Article
|
Effects of aliskiren in diabetic and non-diabetic patients with coronary artery disease: Insights from AQUARIUS.
|
|
Academic Article
|
Management of Hypertension in Diabetic Nephropathy: How Low Should We Go?
|
|
Academic Article
|
Has RAAS Blockade Reached Its Limits in the Treatment of Diabetic Nephropathy?
|
|
Academic Article
|
New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: Considerations for trial design and regulatory approval.
|
|
Academic Article
|
Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin.
|
|
Academic Article
|
Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.
|
|
Academic Article
|
Mineralocorticoid antagonists in chronic kidney disease.
|
|
Academic Article
|
Prior Medications and the Cardiovascular Benefits From Combination Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High-Risk Hypertensive Patients.
|
|
Academic Article
|
Baseline characteristics and enrichment results from the SONAR trial.
|
|
Academic Article
|
Effect of antihypertensive treatment on 24-h blood pressure variability: pooled individual data analysis of ambulatory blood pressure monitoring studies based on olmesartan mono or combination treatment.
|
|
Academic Article
|
Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy.
|
|
Academic Article
|
Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors.
|
|
Academic Article
|
Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN.
|
|
Academic Article
|
Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial.
|
|
Academic Article
|
Non-steroidal mineralocorticoid antagonists: Prospects for renoprotection in diabetic kidney disease.
|
|
Academic Article
|
Cardiovascular Benefits of Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade in Patients Achieving Tight Blood Pressure Control and With Resistant Hypertension.
|
|
Academic Article
|
Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects.
|
|
Academic Article
|
Slowing the Progression of Diabetic Kidney Disease.
|